Needham analyst David Saxon maintained a Hold rating on Sight Sciences (SGHT – Research Report) today. The company’s shares closed yesterday at $13.33.
Saxon covers the Healthcare sector, focusing on stocks such as Alcon, NuVasive, and Staar Surgical. According to TipRanks, Saxon has an average return of -11.9% and a 27.72% success rate on recommended stocks.
Currently, the analyst consensus on Sight Sciences is a Moderate Buy with an average price target of $14.00.
See the top stocks recommended by analysts >>
Based on Sight Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $18.68 million and a GAAP net loss of $22.23 million. In comparison, last year the company earned a revenue of $13.1 million and had a GAAP net loss of $17.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Read More on SGHT:
- Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
- Stifel upgrades Sight Sciences to Buy on potential 2023 upside
- Sight Sciences upgraded to Buy from Hold at Stifel
- Sight Sciences, Verana Health collaborate on glaucoma research
- Sight Sciences price target raised to $15 from $10 at Citi
